Terns Pharmaceuticals Inc (NAS:TERN)
$ 6.01 -0.985 (-14.03%) Market Cap: 388.71 Mil Enterprise Value: 148.48 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 38/100

Terns Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript

May 31, 2023 / 07:00PM GMT
Release Date Price: $10.61 (+0.47%)
Ritu Baral
TD Cowen - Analyst

Good afternoon, everyone, and thanks for joining us today for the Terns Pharmaceutical fireside chat at the Cowen Oncology Innovation Summit. I'm Covering Analyst Ritu Baral. And with us from Terns today, we have CEO Senthil Sundaram.

Sent, thank you so much for joining us today to discuss the Terns's oncology portfolio with a focus on TERN-701.

Senthil Sundaram
Terns Pharmaceuticals, Inc. - CEO

Great. Thank you for having me. Looking forward to it.

Ritu Baral
TD Cowen - Analyst

So I really want to give us enough time to go over 701, which is sort of a new point of intense investor conversation for Terns as a story. You do have other programs. Most know you as historically a NASH play, but there is a growing interest, a growing proportion of investors that looking at your STAMP inhibitor, 701 and almost exclusively, your STAMP inhibitor, 701, as its own promising value driver that could potentially support your entire valuation.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot